Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

267
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
267
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

286
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
286
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

416
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
416
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

238
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
238
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

566
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
566
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.1K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LOCAL RECURRENCE AFTER COLORECTAL ENDOSCOPIC SUBMUCOSAL DISSECTION: A LARGE INTERNATIONAL WESTERN MULTICENTER STUDY.

Gastrointestinal endoscopy·2026
Same author

Reframing Safety: Human Factors for Safer, Smarter, Human-Centered Health Care.

Journal of patient safety·2026
Same author

Gastric peroral endoscopic myotomy for compassionate treatment of symptomatic gastroparesis in patients on chronic opioids.

iGIE : innovation, investigation and insights·2026
Same author

Enhancing Inflammatory Bowel Disease (IBD) competency in gastroenterology fellowship through traditional, digital, and experiential learning pathways.

Inflammatory bowel diseases·2026
Same author

Attaining sustainability in inflammatory bowel disease.

Journal of Crohn's & colitis·2026
Same author

Upadacitinib versus Tofacitinib in the Management of Ulcerative Colitis: A Systematic Review and Meta-Analysis.

Inflammatory intestinal diseases·2026

Related Experiment Video

Updated: Oct 15, 2025

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.2K

Mycophenolate-Induced Colitis: A Rare Side Effect.

Baha Aldeen Bani Fawwaz1, Ahmad Aldwairy2, Aimen Farooq1

  • 1Internal Medicine, AdventHealth Orlando, Orlando, USA.

Cureus
|October 29, 2021
PubMed
Summary

Mycophenolic acid (MPA) can cause colitis, a rare gastrointestinal side effect in transplant patients. Symptoms resolved after stopping MPA, despite normal colonoscopy and biopsy results.

Keywords:
colitismycophenolatemycophenolate side effectsrenal transplant recipientterminal ileitis

More Related Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.3K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.1K

Related Experiment Videos

Last Updated: Oct 15, 2025

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.2K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.3K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.1K

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Transplant Medicine

Background:

  • Mycophenolic acid (MPA) is a crucial immunosuppressant for solid organ transplant recipients.
  • Gastrointestinal (GI) adverse effects are common with MPA, ranging from mild nausea to severe colitis.

Observation:

  • This report details a case of severe diarrhea caused by MPA-induced colitis.
  • Diagnostic challenges arose due to a normal endoscopic appearance and nonspecific pathology findings.

Findings:

  • Discontinuation of MPA led to the complete resolution of colitis symptoms.
  • MPA-induced colitis is a rare complication with unclear management strategies.

Implications:

  • Highlights the need for increased clinical suspicion for MPA-induced colitis, even with atypical findings.
  • Emphasizes the importance of considering medication side effects in transplant patients presenting with GI distress.
  • Suggests MPA cessation as a primary treatment modality for suspected MPA-induced colitis.